ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 419

Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica

Florencia Beatriz Mollerach1, Sebastian Moyano1, Luciano Enrique Pompermayer1, Jose Maximiliano Martinez Perez2, Marina Scolnik3, Javier Rosa1, Luis J. Catoggio4 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology, Internal Medicine Service, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, polymyalgia rheumatica and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  chronic inflammatory diseases are at a substantially increased risk of cardiovascular disease. Framingham risk score (FRS) underestimates cardiovascular risk in many inflammatory diseases. Our objective was to assess the predictive ability of Framingham score model for the 10-year risk of fatal and non-fatal CV diseases in patients with Polymyalgia Rheumatica (PMR).

Methods: we retrospectively reviewed electronic medical records of patients registered in our hospital after year 2000 with the diagnosis of PMR. Patients fulfilling ACR PMR 2012 criteria or with a clinical diagnose made by a rheumatologist were included. Patients with history of cardiovascular event before diagnosis, age greater of 80 years at diagnosis or with less than 10 years of follow up after diagnosis, were excluded. Framingham score was calculated at diagnosis, and based on the FRS, patients were classified into low, intermediate and high-risk categories. Cardiovascular (CV) events such as stroke, transient ischemic attack, coronary arterial disease and peripheral vasculopathy were identified during follow up. Discriminatory ability for CV risk prediction was estimated by the area under the receiver operating characteristic (ROC) curve. Global cardiovascular risk was calculated at 10 years after PMR diagnosis and compared with FRS estimated at diagnosis.

Results: A total of 97 patients were included. Patients characteristics are described in table. Among the 97 patients followed up for a total of 981.5 person-years, 18 CV events occurred with an incidence rate of 1.83 per 100 patient-years (95% CI: 1.1-2.9). There were no differences in clinical characteristics among patients with and without CV events (table). The area under the ROC curve for FRS was 0.61 (95% CI: 0.47- 0.74), indicating low discrimination between patients with and without a CV event. According to FRS 17 (17.5 %), 46 (47.4%) and 34 (35%) patients were classified into low, intermediate and high risk categories respectively. Across the three predicted CV risk groups the observed/predicted CV events (%) were:0.059/0.065; 0.2/0.13; and 0.24/0.26 for low, intermediate and high risk categories respectively. When observed vs predicted CV events in quintiles of CV risk were compared, the following values were obtained: 0.1 vs 0.072; 0.16 vs 0.12; 0.20 vs 0.16; 0.31 vs 0.34.

Conclusion: FRS showed low discrimination capacity between patients with and without a CV event. FRS primarily underestimated CV risk at low and intermediate risk levels, and mostly overestimated CV risk at higher risk levels. Table 1. Patients characteristics

Variables Patients with CV events (n=18) Patients without CV events (n= 79) p value
Females, n (%) 65 (82) 16 (89) 0.495
Mean age at diagnosis (SD) 73.5 (5.5) 71.9 (6.1) 0.3034
Mean erythrocyte sedimentation rate (SD) 60.2 (34.5) 59.9 (26.4) 0.9823
Mean Total cholesterol mg/L (SD) 208.3 (44) 213.7 (39.9) 0.6129
Diabetes at baseline, n (%) 3 (16.7) 5 (6.33) 0.150
Hypertension at baseline, n (%) 14 (77.8) 50 (63.3) 0.242
Obesity (BMI (weight(kg)/Height(m)2)>30, n (%) 5 (27.8) 17 (21.5) 0.567
Median FRS (IQR) 17.8 (12.4-26.6) 14.4 (10.8-21.9) 0.5404
Mean time follow up (years), (SD) 11.6 (1.6) 11.7 (1.7) 0.7761
Smoking, n (%)
Never 12 (67) 68 (86)
Former 3 (16.7) 6 (7.6) 0.177
Current 3 (16.7) 5 (6.3)

Disclosure: F. B. Mollerach, None; S. Moyano, None; L. E. Pompermayer, None; J. M. Martinez Perez, None; M. Scolnik, None; J. Rosa, None; L. J. Catoggio, None; E. R. Soriano, Abbvie, 2,Pfizer Inc, 3,UCB, 2,Janssen Pharmaceutica Product, L.P., 2,Roche Pharmaceuticals, 2,Bristol-Myers Squibb, 2,Abbvie, 5,Pfizer Inc, 5,UCB, 5,Janssen Pharmaceutica Product, L.P., 5,Roche Pharmaceuticals, 5,Novartis Pharmaceutical Corporation, 5,Bristol-Myers Squibb, 5.

To cite this abstract in AMA style:

Mollerach FB, Moyano S, Pompermayer LE, Martinez Perez JM, Scolnik M, Rosa J, Catoggio LJ, Soriano ER. Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/performance-of-framingham-risk-factor-score-in-predicting-cardiovascular-events-in-patients-with-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-framingham-risk-factor-score-in-predicting-cardiovascular-events-in-patients-with-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology